Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.
High Confidence RCTPrimary source: [Open]
Linked compounds: bremelanotide
Outcomes summary
Two randomized Phase 3 trials evaluating bremelanotide for hypoactive sexual desire disorder, reporting efficacy endpoints and adverse event profiles in the studied population.
Limitations
Applicability depends on enrolled population and endpoints; trial design and outcome measures shape interpretability.
Notes
Primary source: PMID 31599840.